Last $46.77 USD
Change Today -0.29 / -0.62%
Volume 738.7K
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 8000

Fax:

nverts in vivo into aripiprazole, a molecule that is commercially available under the name ABILIFY. Aripiprazole lauroxil is the company’s first product candidate to utilize its proprietary LinkeRx product platform. ALKS 33: ALKS 33 is an oral opioid modulator characterized by limited hepatic metabolism and durable pharmacologic activity in modulating brain opioid receptors. ALKS 33 has completed a phase 2 study in alcohol dependence and is being evaluated as a component of ALKS 5461 and ALKS 3831. ALKS 5461: ALKS 5461 is a proprietary investigational medicine with a novel mechanism for the treatment of major depressive disorder. The mechanism of action for ALKS 5461 in the treatment of depressive symptoms is based on modulation of the opioid system in the brain, employing a balanced combination of agonism and antagonism of opioid receptors. ALKS 5461 consists of buprenorphine, a partial agonist, and ALKS 33, a potent mu-opioid antagonist, and is designed to be a once-daily, non-addictive medicine. ZOHYDRO ER: ZOHYDRO ER (hydrocodone bitartrate extended-release capsules) is a novel, oral, single-entity (without acetaminophen), controlled-release formulation of hydrocodone in development by Zogenix, Inc. for the U.S. market. ZOHYDRO ER utilizes the company’s oral controlled-release technology, which enables longer-lasting pain relief with fewer daily doses than the commercially available formulations of hydrocodone. The company has also entered into a license and distribution agreement with Paladin Labs Inc. in respect of ZOHYDRO ER in Canada. ALKS 3831: ALKS 3831 is a proprietary investigational medicine designed as a spectrum treatment for schizophrenia. ALKS 3831 includes ALKS 33, a novel opioid modulator that acts as a potent mu-opioid antagonist, in combination with the established antipsychotic drug olanzapine. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, and offer the therapeutic benefits of olanzapine to a range of patients with schizophrenia. Other: A three-month formulation of INVEGA SUSTENNA is in development by Janssen Research & Development, LLC. In April 2013, Acorda reported positive results from an 83-subject proof-of-concept study of dalfampridine-ER 10 mg in the treatment of post-stroke deficits, as demonstrated by improvement in walking measured by the Timed 25-Foot Walk. Collaborative Arrangements RISPERDAL CONSTA: Under a product development agreement, the company collaborated with Janssen on the development of RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to the company for the development of RISPERDAL CONSTA, and Janssen is responsible for securing all necessary regulatory approvals for the product. Under license agreements, the company granted Janssen and an affiliate of Janssen worldwide licenses to use and sell RISPERDAL CONSTA. INVEGA SUSTENNA/XEPLION: Under the company’s license agreement with Janssen Pharmaceutica N.V., the company granted Janssen a worldwide license under its NanoCrystal technology to develop, commercialize, and manufacture INVEGA SUSTENNA/XEPLION and related products. Acorda: Under an amended and restated license agreement, the company granted Acorda a worldwide license to use and sell, and solely in accordance with its supply agreement, to make or have made, AMPYRA/FAMPYRA. Under its commercial manufacturing supply agreement with Acorda, the company manufactures and supplies AMPYRA/FAMPYRA for Acorda (and its sub-licensees). Bristol-Myers: The company has a development and license agreement with Amylin, a wholly-owned subsidiary of Bristol-Myers, for the development of exendin products falling within the scope of its patents, which include the once-weekly formulation of exenatide, BYDUREON. Marketing, Sales, and Distribution The company is responsible for marketing VIVITROL in the U.S. Its sales force for VIVITROL in the U.S. consists of approximately 70 individuals. VIVITROL is sold directly to pharmaceutical wholesalers, specialty pharmacies, and a specialty distributor. Customers The company’s customers include McKesson Corporation, CVS Caremark

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $46.77 USD -0.29

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $59.19 USD -2.80
Jazz Pharmaceuticals Plc $143.91 USD -1.44
Lupin Ltd 986.70 INR +4.10
Nektar Therapeutics $11.96 USD -0.30
Pacira Pharmaceuticals Inc/DE $68.30 USD -3.43
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings 100.0x
Price/Sales 11.2x
Price/Book 6.1x
Price/Cash Flow 90.9x
TEV/Sales 10.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.